Yes, oxybutynin is an anticholinergic medication. It is classified specifically as a muscarinic antagonist, meaning it blocks the chemical messenger acetylcholine from activating certain receptors throughout the body. This is how it treats overactive bladder, but it’s also why the drug carries a notable side effect profile that’s worth understanding.
How Oxybutynin Works
Oxybutynin blocks three types of muscarinic receptors (M1, M2, and M3) that normally respond to acetylcholine. In the bladder, blocking these receptors relaxes the smooth muscle wall, increases bladder capacity, and reduces the involuntary contractions that cause sudden urges to urinate. The FDA first approved it in 1975 for overactive bladder symptoms like urinary urgency, frequency, and urge incontinence. It’s also approved for children aged 6 and older with bladder overactivity related to neurological conditions such as spina bifida.
The problem is that muscarinic receptors aren’t only in the bladder. They’re in your salivary glands, gut, eyes, and brain. Blocking them everywhere at once is what produces the classic anticholinergic side effects people associate with this drug.
Common Anticholinergic Side Effects
Dry mouth is the most frequently reported issue and, for many people, the reason they stop taking the medication. With the immediate-release oral form, dry mouth affects anywhere from 17% to 93% of patients depending on the study and dose. Constipation, blurred vision, and dizziness are also common. These side effects stem largely from a metabolite the liver produces when it processes oral oxybutynin. This byproduct, created during what’s called first-pass metabolism, is considered more responsible for anticholinergic symptoms than oxybutynin itself.
Oral vs. Transdermal Formulations
Because so many side effects trace back to liver metabolism of the oral form, transdermal versions (patches and gels) were developed to bypass the liver and reduce that problematic metabolite. The difference is significant. In clinical trials, dry mouth with the oxybutynin patch occurred in about 7% of patients, a rate that did not differ significantly from placebo. One gel formulation showed dry mouth in roughly 6.9% of users compared to 2.8% on placebo.
If you’re experiencing bothersome anticholinergic side effects on the oral tablet, the transdermal route delivers the same active drug with considerably less systemic anticholinergic burden. The trade-off is that patches can cause skin irritation at the application site in a small percentage of users.
Cognitive Risks in Older Adults
This is where oxybutynin’s anticholinergic classification carries its most serious implications. The American Geriatrics Society lists oxybutynin among drugs with strong anticholinergic properties in its 2023 Beers Criteria, a widely used guide for medications that are potentially inappropriate for adults over 65. The guidance recommends avoiding anticholinergics in older adults with dementia, cognitive impairment, delirium risk, or a history of falls.
A large nested case-control study published in BMJ Medicine examined dementia risk in adults aged 55 and older who used anticholinergic bladder medications. The findings showed a clear dose-response pattern for oxybutynin. People with minimal use (under 90 days of standard doses) had a 4% increased odds of dementia compared to nonusers. Those with one to three years of cumulative use had 31% higher odds. And people with more than three years of daily use still showed a 28% increase. These numbers represent associations, not proof that oxybutynin directly causes dementia, but the pattern was consistent and oxybutynin was among the bladder medications most strongly linked to the risk.
Stacking multiple anticholinergic medications compounds the concern. The Beers Criteria specifically warns against combining drugs with anticholinergic properties because doing so increases the risk of cognitive decline, delirium, and falls.
Who Should Avoid Oxybutynin
The FDA label lists several absolute contraindications. You should not take oxybutynin if you have urinary retention (the inability to fully empty your bladder), gastric retention or other conditions involving severely slowed digestive motility, or uncontrolled narrow-angle glaucoma. It’s also contraindicated if you’re at elevated risk for any of these conditions. These restrictions exist precisely because an anticholinergic drug will worsen each of them: it slows gut movement, can increase eye pressure, and reduces bladder contractions needed for voiding.
Why the Classification Matters
Knowing oxybutynin is an anticholinergic isn’t just a pharmacology detail. It has practical consequences for how you manage your medications. Many common drugs have some degree of anticholinergic activity, including certain antihistamines, antidepressants, and sleep aids. If you’re already taking one of those and add oxybutynin, the combined anticholinergic load on your body increases. This cumulative effect, sometimes called anticholinergic burden, is what geriatricians and pharmacists track when reviewing medication lists, particularly for older patients.
For younger adults with overactive bladder and no other anticholinergic medications, oxybutynin remains an effective and widely used option. For older adults or anyone on multiple medications, the anticholinergic classification is a signal to weigh the benefits against a real set of cognitive and physical risks, and to consider whether a transdermal formulation or a different drug class might be a better fit.